| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-543 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2016-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_369bde51c826ad5336388f378b146974
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f0b9ad4fa5acfdd6eb951323b7d3072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c01bf079ec4e8891678fe464883fe9ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db84a796f37866e564f30ed9ad21faa8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce4bfae40819510db64caebb316bb1e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b10fbd90e703904052a2fd79cd80ef7c |
| publicationDate |
2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11326211-B2 |
| titleOfInvention |
Blood-based biomarkers of tumor sensitivity to PD-1 antagonists |
| abstract |
The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results. |
| priorityDate |
2015-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |